中文产业新闻评分67Chinese source
诺和诺德 ziltivekimab ZEUS 三期心血管主要终点未达，90% 降幅为何未换来获益
90%的降幅为何换不来终点获益？诺和诺德 ZEUS 试验的跨领域启示
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
90%的降幅为何换不来终点获益？诺和诺德 ZEUS 试验的跨领域启示
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.